Silvercrest Asset Management Group LLC Increases Holdings in Encompass Health Co. (NYSE:EHC)

Silvercrest Asset Management Group LLC grew its position in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 114.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 340,091 shares of the company's stock after purchasing an additional 181,693 shares during the period. Silvercrest Asset Management Group LLC owned about 0.34% of Encompass Health worth $31,407,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Miracle Mile Advisors LLC boosted its holdings in shares of Encompass Health by 3.0% during the fourth quarter. Miracle Mile Advisors LLC now owns 3,835 shares of the company's stock worth $354,000 after purchasing an additional 112 shares during the period. Park Avenue Securities LLC raised its holdings in shares of Encompass Health by 44.7% during the fourth quarter. Park Avenue Securities LLC now owns 6,737 shares of the company's stock valued at $622,000 after acquiring an additional 2,082 shares in the last quarter. USA Financial Formulas lifted its stake in Encompass Health by 7.1% in the fourth quarter. USA Financial Formulas now owns 3,642 shares of the company's stock worth $336,000 after acquiring an additional 240 shares during the period. Tompkins Financial Corp bought a new stake in Encompass Health in the fourth quarter valued at $46,000. Finally, Merit Financial Group LLC purchased a new position in Encompass Health during the 4th quarter valued at $374,000. 97.25% of the stock is owned by institutional investors.

Insider Activity

In related news, insider Elissa Joy Charbonneau sold 4,279 shares of the company's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $116.61, for a total value of $498,974.19. Following the completion of the transaction, the insider now owns 11,958 shares of the company's stock, valued at approximately $1,394,422.38. This represents a 26.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Mark J. Tarr sold 118,384 shares of the business's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the completion of the transaction, the chief executive officer now directly owns 527,070 shares in the company, valued at $64,054,817.10. This trade represents a 18.34% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 132,663 shares of company stock valued at $16,034,082 in the last 90 days. Company insiders own 2.00% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on EHC. William Blair reiterated an "outperform" rating on shares of Encompass Health in a research report on Friday, February 7th. StockNews.com upgraded shares of Encompass Health from a "hold" rating to a "buy" rating in a report on Sunday, May 11th. UBS Group raised their price objective on shares of Encompass Health from $117.00 to $130.00 and gave the stock a "buy" rating in a report on Monday, April 28th. Royal Bank of Canada raised their price objective on shares of Encompass Health from $110.00 to $125.00 and gave the stock an "outperform" rating in a report on Monday, April 28th. Finally, KeyCorp raised their price objective on shares of Encompass Health from $120.00 to $122.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $120.86.

Encompass Health Stock Up 0.4%

Shares of EHC stock traded up $0.49 during trading hours on Tuesday, hitting $121.67. 751,820 shares of the company's stock traded hands, compared to its average volume of 695,950. The stock's fifty day simple moving average is $105.97 and its two-hundred day simple moving average is $100.90. Encompass Health Co. has a 12-month low of $82.74 and a 12-month high of $121.98. The stock has a market cap of $12.26 billion, a price-to-earnings ratio of 27.28, a PEG ratio of 2.31 and a beta of 0.91. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84.

Encompass Health (NYSE:EHC - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.18. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter last year, the firm earned $1.12 earnings per share. The firm's quarterly revenue was up 10.6% compared to the same quarter last year. On average, analysts expect that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Tuesday, July 1st will be given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date of this dividend is Tuesday, July 1st. Encompass Health's payout ratio is 14.05%.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.